Best Practices for Managing Tyrosine Kinase Inhibitor-Related Adverse Events

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Zofia Piotrowska, MD, discusses the management of paronychia associated with EGFR TKIs.

An overview of EGFR tyrosine kinase inhibitors (TKIs), common adverse events with EGFR TKI therapy and management strategies for them, and additional notable toxicities with EGFR TKIs.

Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.

Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.